Inventor · disambiguated record
Robert Goodenow
Also filed as: GOODENOW ROBERT · GOODENOW ROBERT S
12 granted patents·15 pending applications·70 citations·filing 1993–2025
89Inventor score
Files withSYNDAX PHARMACEUTICALS INC10HUYABIO INT LLC9UNIV CALIFORNIA4HUYA BIOSCIENCE INT LLC2BURKE KONRAD1
Top patents by PatentIndex Score
27 records- 0192US11020374B2Sulcardine saltsHUYA BIOSCIENCE INT LLC·Filed 2020·Granted Jun 1, 2021·4 cites·19 claims
- 0289US11813245B2Sulcardine administration for treatment of acute atrial fibrillationHUYABIO INT LLC·Filed 2021·Granted Nov 14, 2023·2 cites·45 claims
- 0385US12097203B2Combination therapies comprising SHP2 inhibitors and PD-1 inhibitorsHUYABIO INT LLC·Filed 2022·Granted Sep 24, 2024·1 cites·31 claims
- 0484US10226472B2Methods for the treatment of breast cancerGOODENOW ROBERT·Filed 2012·Granted Mar 12, 2019·14 cites·18 claims
- 0580US11324822B2Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2016·Granted May 10, 2022·3 cites·24 claims
- 0676US12465587B2Sulcardine administration for treatment of acute atrial fibrillationHUYABIO INT LLC·Filed 2023·Granted Nov 11, 2025·0 cites·23 claims
- 0776US2024398944A1Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0870US2025144072A9Sulcardine saltsHUYABIO INT LLC·Filed 2022·Application pending·0 cites
- 0970US2023022573A1Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1068US12390469B2SHP2 inhibitor monotherapy and uses thereofHUYABIO INT LLC·Filed 2022·Granted Aug 19, 2025·0 cites·26 claims
- 1168US2025367204A1Shp2 inhibitor monotherapy and uses thereofHUYABIO INT LLC·Filed 2025·Application pending·0 cites
- 1266US2010305167A1Administration of an Inhibitor of HDACSYNDAX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 1365US11426382B2Sulcardine saltsHUYABIO INT LLC·Filed 2020·Granted Aug 30, 2022·0 cites·3 claims
- 1460US5385888AClass I MHC modulation or surface receptor activityUNIV CALIFORNIA·Filed 1993·Granted Jan 31, 1995·24 cites·2 claims
- 1559US5639458AClass I MHC modulation of surface receptor activityUNIV CALIFORNIA·Filed 1993·Granted Jun 17, 1997·11 cites·16 claims
- 1658US2009149511A1Administration of an Inhibitor of HDAC and an mTOR InhibitorSYNDAX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 1757US2013303575A1Administration of an inhibitor of hdacBURKE KONRAD·Filed 2013·Application pending·0 cites
- 1855US2022370456A1Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitorsHUYABIO INT LLC·Filed 2022·Application pending·0 cites
- 1954US2022110924A1Methods and compositions for genetic modulation of tumor microenvironmentsHUYABIO INT LLC·Filed 2021·Application pending·0 cites
- 2051US2010267779A1Novel Compounds and Methods of Using ThemSYNDAX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2151US2010298270A1Novel Compounds and Methods of Using ThemSYNDAX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2249US2019343844A1Methods for the treatment of breast cancerSYNDAX PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2347US5853999AMethods of screening for agents that inhibit interaction between MHC class I antigens and a cell surface receptorUNIV CALIFORNIA·Filed 1995·Granted Dec 29, 1998·6 cites·38 claims
- 2446US6028171AClass I MHC modulation of surface receptor activityUNIV CALIFORNIA·Filed 1995·Granted Feb 22, 2000·5 cites·16 claims
- 2546US2013150386A1Methods for the treatment of lung cancerSYNDAX PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 2644US2019046513A1Combination therapies of hdac inhibitors and tubulin inhibitorsHUYA BIOSCIENCE INT LLC·Filed 2017·Application pending·0 cites
- 2737US2018353602A1Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert Goodenow files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →